Eva Medtec Launches Neuroglide™ Pain Relief and Recovery System

With Early Release of 250 Units for Online Purchase

Eva Medtec, Inc. is excited to announce that its flagship product, the Neuroglide Back/Neck Pad, is available for purchase by the general public.

Sporting an FDA clearance for pain relief, a limited, 250-unit release of this innovative neck and back pain therapy device can now be purchased here, with a $250.00 discount.

The Neuroglide Back/Neck Pad is the first of a system of automated therapy devices that provide effective, convenient, and sustainable pain management solutions for people living with chronic pain, who need to relax, relieve and recover.

The technology is designed to emulate a therapeutic modality called manual lymphatic drainage (MLD). MLD triggers the body’s parasympathetic nervous system, activating powerful natural relaxation and pain relief pathways.

Neuroglide’s patented system includes a Controller Unit, disruptive new valve module technology, and unique inflatable air channels which have been precisely engineered to deliver the proven benefits of MLD therapy in the comfort of one’s home, relieving pain without the need for pharmaceuticals or expensive in-person sessions while offering improved recovery and performance, relaxation, and stress relief.

Eva Medtec founder/CEO and Neuroglide inventor, Irene Waldridge, previously founded Tactile Medical, where she held four patents as the inventor of the Flexitouch® System for the treatment of lymphedema and venous insufficiency. Tactile Medical is currently valued at about $1B on revenues approximating $190M.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”